P2Y12 Platelet Inhibitor [EPC]

This page covers all P2Y12 Platelet Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12, P2Y purinoceptor 12, HMG-CoA reductase and P2Y12 receptor.

Targets

Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12 · P2Y purinoceptor 12 · HMG-CoA reductase and P2Y12 receptor

Marketed (4)

• Brilinta · AstraZeneca · Cardiovascular · 1100
• Effient · Cosette · Metabolic · 400
  Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots.
• Kengreal · Chiesi · Metabolic · 200
  Kengreal blocks the action of ADP on platelets, preventing platelet activation and aggregation.
• atorvastatin and clopidogrel · Ospedale Misericordia e Dolce · Cardiovascular
  This combination reduces cholesterol levels and prevents blood clots by inhibiting HMG-CoA reductase and platelet aggregation, respectively.

Patent intelligence

• p2y12 platelet inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates